Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Basiliximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Cutaneous T-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 20 Mar 2025 Status changed from active, no longer recruiting to completed.
- 18 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.